FindTrial
Sign In

A comparitive study of intravitreal aflibercept 1.0mg versus 2.0 mg in management of central diabetic macular edema

A comparative study of two different doses of intravitreal Aflibercept 1.0 mg versus 2.0 mg in management of naive centre involving Diabetic Macular Edema

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/030058
Enrollment
70
Registered
2020-12-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H358- Other specified retinal disorders

Interventions

Intervention1: Intravitreal injection of 1.0 mg Aflibercept.: Intravitreal injections of 1.0 mg Aflibercept will be administered at 0 week, 8 week and 16 weeks based on change in macular edema for a

Sponsors

Command Hospital Chandimandir
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 age more then 18 years both male and female 2 centre involving diabetic macular edema

Exclusion criteria

Exclusion criteria: 1 media opacity precluding OCT measurements at inception 2 prior laser photocoagulation 3 prior antivegf administartion or intravitreal steroids

Design outcomes

Primary

MeasureTime frame
Best corrected visual acuity and Central macular thickness on Optical Coherence Tomography assessment.Timepoint: At 0,4,8,12,16,20 and 24 weeks—

Secondary

MeasureTime frame
Contrast on Pelli Robson chartTimepoint: 0,4,8,12,16,20 and 24 weeks—

Countries

India

Contacts

Public ContactLt Col Pradeep Kumar

Command Hospital, Chandimandir

pradeepthakurella@yahoo.com9560034515

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026